BackEvommune Overview
Evommune, Inc.

Evommune Target Price

Analysts' average 12-month price target for Evommune is $28.

Get informed when a big investor buys or sells

+ Follow

Share Price

$9.45

Average Target Price

$27.83194.5% upside

6 analysts in the last 4 months

High: $50 | Low: $18

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-09-09Stifel NicolausAlex Thompson$30217.5% upsideOpen
2026-09-09Raymond James$1890.5% upsideOpen
2026-09-09Leerink Partners$22132.8% upsideOpen
2026-09-09RBC CapitalBrian Abrahams$21122.2% upsideOpen
2026-06-30Morgan Stanley$26175.1% upsideOpen
2026-05-26H.C. WainwrightMitchell Kapoor$50429.1% upsideOpen
2026-05-11Morgan Stanley$55482% upsideOpen
2026-02-18Morgan StanleyJudah Frommer$54471.4% upsideOpen
2026-02-10Evercore ISI$55482% upsideOpen
2026-02-10H.C. WainwrightMitchell Kapoor$65587.8% upsideOpen
2026-01-22Oppenheimer$42344.4% upsideOpen
2026-01-07Raymond James$40323.3% upsideOpen
2026-01-06H.C. WainwrightMitchell Kapoor$35270.4% upsideOpen
2025-12-01Leerink PartnersThomas Smith$42344.4% upsideOpen
2025-12-01Evercore ISI$40323.3% upsideOpen
2025-12-01Morgan StanleyJudah Frommer$36281% upsideOpen

Evommune (EVMN) FAQ

Evommune (EVMN) currently reports a target price of $28. Use the charts on this page to explore Evommune's target price history and peer comparisons.

Analysts' average 12-month price target for Evommune is $28, about 194.5% upside from the current share price of $9.45. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $28, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Evommune, and consider following EVMN for alerts when major investors trade the stock.

Evommune is classified in the Healthcare sector. On target price, it currently shows $28. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EVMN with unrelated industries.